A study of Medtronic's drug-coated balloon in dialysis patients demonstrated an 86.1% likelihood the vessel would remain open versus 68.9% in the percutaneous transluminal angioplasty control group. The data show the device could be beneficial for high-risk patients, said Mark Pacyna, vice president of Medtronic's peripheral vascular business.
Medtronic reports positive results from DCB study in dialysis patients
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.